| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 02/25/2010 | WO2010022240A1 Pyrrolo [ 1, 2 -b] pyridazine derivatives and their use as hif modulators |
| 02/25/2010 | WO2010022238A2 Anti-flavivirus therapeutic |
| 02/25/2010 | WO2010022217A1 Combinations comprising bicyclic s1p lyase inhibitors |
| 02/25/2010 | WO2010022201A2 Folinic acid derivatives for promoting bone growth |
| 02/25/2010 | WO2010022196A2 [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase |
| 02/25/2010 | WO2010022169A1 Methods of inhibiting fgfr3 signaling |
| 02/25/2010 | WO2010022159A1 Cyclohexylamines, phenylamines and uses thereof |
| 02/25/2010 | WO2010022148A1 Methods for the preparation of irciniastatin and analogs thereof |
| 02/25/2010 | WO2010022140A1 Compositions and methods of using (r)-pramipexole |
| 02/25/2010 | WO2010022139A1 Regulation of integrin surface expression |
| 02/25/2010 | WO2010022128A1 Ethenyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| 02/25/2010 | WO2010022126A1 Azo-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| 02/25/2010 | WO2010022125A1 Ethynyl-substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| 02/25/2010 | WO2010022121A1 Substituted pyridine and pyrimidine derivatives and their use in treating viral infections |
| 02/25/2010 | WO2010022081A1 Triazolopyridine compounds as pim kinase inhibitors |
| 02/25/2010 | WO2010022076A1 Triazolopyridine compounds as pim kinase inhibitors |
| 02/25/2010 | WO2010022052A1 Polymorphic form of granisetron hydrochloride and methods of making the same |
| 02/25/2010 | WO2010022051A2 Disruptors of early/recycling endosomes |
| 02/25/2010 | WO2010022043A2 Targeting of histone deacetylase 2 and protein kinase ck2 for treatment of inflammatory diseases |
| 02/25/2010 | WO2010022033A2 Therapeutic substituted pyrroles |
| 02/25/2010 | WO2010022031A1 Topical hydrogel composition |
| 02/25/2010 | WO2010022017A2 Method and composition for enhancing hematopoietic stem cell mobilization |
| 02/25/2010 | WO2010021934A2 Azaindole inhibitors of iap |
| 02/25/2010 | WO2010021930A1 Prevention and treatment of mrsa infections with chitosan-derivatives |
| 02/25/2010 | WO2010021928A1 Organoarsenic compounds and methods for the treatment of cancer |
| 02/25/2010 | WO2010021919A1 3- and 6-quinolines with n-attached heterocyclic cgrp receptor antagonists |
| 02/25/2010 | WO2010021918A1 Compounds as kinase inhibitors |
| 02/25/2010 | WO2010021882A2 Cold menthol receptor antagonists |
| 02/25/2010 | WO2010021865A1 Novel lipid nanoparticles and novel components for delivery of nucleic acids |
| 02/25/2010 | WO2010021843A1 Use of antifolates in patients with detectable levels of tff-1 for the cancer treatment |
| 02/25/2010 | WO2010021797A1 Condensed heterocyclic compounds having 5-ht6 receptor affinity |
| 02/25/2010 | WO2010021770A1 Heterogeneous polymeric micelles for intracellular delivery |
| 02/25/2010 | WO2010021766A1 Hydroxybutyrate ester and medical use thereof |
| 02/25/2010 | WO2010021750A2 Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer |
| 02/25/2010 | WO2010021717A2 Hcv protease inhibitors |
| 02/25/2010 | WO2010021713A1 Use of d-ribose for fatigued subjects |
| 02/25/2010 | WO2010021702A1 Self-avoiding molecular recognition systems in dna amplification |
| 02/25/2010 | WO2010021681A2 Compositions and methods for treatment of viral diseases |
| 02/25/2010 | WO2010021636A1 Corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
| 02/25/2010 | WO2010021609A1 Solubility and stability enhancing pharmaceutical formulation |
| 02/25/2010 | WO2010021608A1 Solubility enhancing pharmaceutical formulation |
| 02/25/2010 | WO2010021555A1 Anthelmintic compositions |
| 02/25/2010 | WO2010021514A2 Pharmaceutical composition containing glutamine for treating atopic dermatitis |
| 02/25/2010 | WO2010021473A2 Pharmaceutical formulation |
| 02/25/2010 | WO2010021415A1 Method for controlling cancer metastasis or cancer cell migration by modulating the cellular level of lysyl trna synthetase |
| 02/25/2010 | WO2010021389A1 Nucleic acid capable of inhibiting expression of bcl-2 protein |
| 02/25/2010 | WO2010021385A1 Therapeutic agent for anca-related vasculitis |
| 02/25/2010 | WO2010021381A1 Fused heterocyclic derivative and use thereof |
| 02/25/2010 | WO2010021370A1 Oral composition |
| 02/25/2010 | WO2010021351A1 Cycloalkylamine derivative |
| 02/25/2010 | WO2010021247A1 Pharmaceutical preparation, food or beverage having inhibitory activity on serotonin transporter |
| 02/25/2010 | WO2010021149A1 Spiro compound capable of inhibiting acid secretion |
| 02/25/2010 | WO2010021129A1 Apoptosis inhibitor |
| 02/25/2010 | WO2010021064A1 Therapeutic agent for fibromyalgia syndrome and therapeutic agent for pain due to vascular smooth muscle spasm |
| 02/25/2010 | WO2010021034A1 Skin preparation for external use |
| 02/25/2010 | WO2010020981A1 A3 adenosine receptor allosteric modulators |
| 02/25/2010 | WO2010020970A1 Single unit oral dose pharmaceutical composition comprising levodopa, carbidopa and entacapone or salts thereof |
| 02/25/2010 | WO2010020969A1 An extended release pharmaceutical composition of entacapone or salts thereof |
| 02/25/2010 | WO2010020959A1 Resveratrol-containing composition for treating heart failure |
| 02/25/2010 | WO2010020920A2 Anti-parkinsonian compound acetylsalicylic acid maltol ester |
| 02/25/2010 | WO2010020905A1 Pyrrolo[2,3-d]pyrimidine compounds |
| 02/25/2010 | WO2010020904A2 Cardioplegic preparation |
| 02/25/2010 | WO2010020882A1 New combination of active ingredients containing an alpha-1antagonist and a pde 4 inhibitor |
| 02/25/2010 | WO2010020881A1 New therapeutic use of drotaverine |
| 02/25/2010 | WO2010020810A1 2-(imidaz0lylamin0)-pyridine derivatives and their use as jak kinase inhibitors |
| 02/25/2010 | WO2010020799A2 Composition |
| 02/25/2010 | WO2010020789A2 Medicament and treatment for infections |
| 02/25/2010 | WO2010020786A1 Organ protection |
| 02/25/2010 | WO2010020762A1 1,5-diaryl-pyrazoles and their use as cannabinoid receptor neutral antagonists |
| 02/25/2010 | WO2010020703A1 Mek 1/2 inhibitors for the treatment of peritoneal fibrosis |
| 02/25/2010 | WO2010020676A1 The use of topoisomerase type i inhibitors to treat viral infections |
| 02/25/2010 | WO2010020675A1 Pyrrolopyrimidine compounds as cdk inhibitors |
| 02/25/2010 | WO2010020672A1 Novel phenyl-quinoline-carboxylic acid pyridine derivatives useful as modulators of nicotinic acetylcholine receptors |
| 02/25/2010 | WO2010020663A1 New (poly)aminoalkylaminoalkylamide, alkyl-urea, or alkyl-sulfonamide derivatives of epipodophyllotoxin, a process for preparing them, and application thereof in therapy as anticancer agents |
| 02/25/2010 | WO2010020651A1 Treatment of anxiety disorders |
| 02/25/2010 | WO2010020647A2 New method for identifying compounds useful for treating and/or preventing disease-associated bone loss |
| 02/25/2010 | WO2010020639A1 Arabinoxylans for modulating the barrier function of the intestinal surface |
| 02/25/2010 | WO2010020610A1 Compounds for the treatment of peripheral neuropathies |
| 02/25/2010 | WO2010020609A1 Amino alcohol derivatives for the treatment of demyelinating peripheral neuropathies |
| 02/25/2010 | WO2010020602A1 Dabigatran for percutaneous interventional cardiac catheterisation |
| 02/25/2010 | WO2010020601A1 Dabigatran in tumour therapy |
| 02/25/2010 | WO2010020600A1 Use of dabigatranetexilate for treating patients with pulmonary hypertension |
| 02/25/2010 | WO2010020593A1 Treatment of an autoimmune disease using il-18 antagonists |
| 02/25/2010 | WO2010020585A1 Serotonin reuptake inhibitors for the treatment of rett syndrome |
| 02/25/2010 | WO2010020556A1 New bradykinin b1 antagonists |
| 02/25/2010 | WO2010020548A1 Glyt1 receptor antagonists |
| 02/25/2010 | WO2010020432A2 Compounds for treatment of duchenne muscular dystrophy |
| 02/25/2010 | WO2010020423A2 Methods for treating bleeding disorders |
| 02/25/2010 | WO2010020379A1 Composition for prevention and treatment of allergic and/or inflammatory diseases |
| 02/25/2010 | WO2010020366A1 Azabicyclic substituted 5-aminopyrazoles and the use thereof |
| 02/25/2010 | WO2010020363A1 Substituted 5-aminopyrazoles and use thereof |
| 02/25/2010 | WO2010020308A1 7-azaindole derivatives |
| 02/25/2010 | WO2010020307A2 Indazole-5-carboxylic acid hydrazide derivatives |
| 02/25/2010 | WO2010020305A1 Oxadiazole derivatives for treating diabetes |
| 02/25/2010 | WO2010020276A1 Treatment of coccidian parasites |
| 02/25/2010 | WO2010020136A1 Sterilizing polymer and method of preparation thereof |
| 02/25/2010 | WO2010020057A1 Treatment and/or Prevention of Peanut Induced Anaphylaxis |
| 02/25/2010 | WO2010020055A1 Small molecule inhibitors of n-terminus activation of the androgen receptor |
| 02/25/2010 | WO2010020004A1 Compositions and methods for inhibition of adipogenesis and the treatment of obesity |
| 02/25/2010 | WO2010020000A1 Novel compounds and their uses in diagnosis |